{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:23:55Z","timestamp":1792232635914,"version":"4.4.0"},"reference-count":74,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Laboratory Medicine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.cll.2026.02.003","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T12:25:00Z","timestamp":1773491100000},"page":"243-258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacologic Factor XI\/XIa Inhibitors"],"prefix":"10.1016","volume":"46","author":[{"given":"Jeffrey I.","family":"Weitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gailani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cll.2026.02.003_bib1","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1182\/blood.2023020722","article-title":"Targeting factor XI and factor XIa to prevent thrombosis","volume":"143","author":"Gailani","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.cll.2026.02.003_bib2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/jth.15126","article-title":"New anticoagulants: moving beyond the direct oral anticoagulants","volume":"19","author":"Fredenburgh","year":"2021","journal-title":"J Thromb Haemostasis"},{"key":"10.1016\/j.cll.2026.02.003_bib3","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1161\/CIRCRESAHA.115.306841","article-title":"Global burden of thrombosis: epidemiologic aspects","volume":"118","author":"Wendelboe","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.cll.2026.02.003_bib4","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1365-2141.1990.00122.x-i1","article-title":"Effect of warfarin on plasma concentrations of vitamin K dependent coagulation factors in patients with stable control and monitored compliance","volume":"74","author":"Kumar","year":"1990","journal-title":"Br J Haematol"},{"issue":"41","key":"10.1016\/j.cll.2026.02.003_bib5","first-page":"1633","article-title":"American Heart Association\/American College of Cardiology Foundation guide to warfarin therapy","volume":"107","author":"Hirsh","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.cll.2026.02.003_bib6","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/jhg.2013.40","article-title":"Pharmacogenetics of warfarin: challenges and opportunities","volume":"58","author":"Lee","year":"2013","journal-title":"J Hum Genet"},{"key":"10.1016\/j.cll.2026.02.003_bib7","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/CIRCOUTCOMES.108.796185","article-title":"Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review","volume":"1","author":"Wan","year":"2008","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.cll.2026.02.003_bib8","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1161\/01.STR.26.8.1471","article-title":"Oral anticoagulants and intracranial bleeding","volume":"26","author":"Hart","year":"1995","journal-title":"Stroke"},{"key":"10.1016\/j.cll.2026.02.003_bib9","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood-2016-08-731638","article-title":"Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy","volume":"129","author":"Lopes","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.cll.2026.02.003_bib10","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017559","article-title":"Direct oral anticoagulant use: a practical guide to common clinical challenges","volume":"9","author":"Chen","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cll.2026.02.003_bib11","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.jacc.2023.10.038","article-title":"When direct oral anticoagulants should not be standard treatment: JACC state-of-the-art review","volume":"83","author":"Bejjani","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cll.2026.02.003_bib12","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.7326\/M21-1094","article-title":"Long-term risk for major bleeding during extended oral anticoagulant therapy for first unprovoked venous thromboembolism: a systematic review and meta-analysis","volume":"174","author":"Khan","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cll.2026.02.003_bib13","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.cll.2026.02.003_bib14","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","article-title":"Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials","volume":"124","author":"van Es","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.cll.2026.02.003_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-022558","article-title":"Anticoagulation therapy in patients with stroke and atrial fibrillation: a registry-based study of acute stroke care in surrey, UK","volume":"8","author":"Han","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.cll.2026.02.003_bib16","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jacc.2021.06.010","article-title":"Factor XI inhibition to uncouple thrombosis from hemostasis: JACC review topic of the week","volume":"78","author":"Hsu","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cll.2026.02.003_bib17","series-title":"Hematology: basic principles and practice","first-page":"1906","article-title":"Overview of hemostasis and thrombosis","author":"Fredenbergh","year":"2023"},{"key":"10.1016\/j.cll.2026.02.003_bib18","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1182\/bloodadvances.2024014845","article-title":"Membrane-bound model of the ternary complex between factor VIIa\/tissue factor and factor X","volume":"9","author":"Muller","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.cll.2026.02.003_bib19","doi-asserted-by":"crossref","first-page":"5703","DOI":"10.1016\/S0021-9258(19)70686-3","article-title":"Kinetics of factor IX activation via the extrinsic pathway. Dependence of Km on tissue factor","volume":"255","author":"Zur","year":"1980","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cll.2026.02.003_bib20","doi-asserted-by":"crossref","first-page":"7623","DOI":"10.1073\/pnas.87.19.7623","article-title":"Hemophilia as a defect of the tissue factor pathway of blood coagulation: effect of factors VIII and IX on factor X activation in a continuous-flow reactor","volume":"87","author":"Repke","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.cll.2026.02.003_bib21","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/hae.14687","article-title":"Global epidemiology of factor XI deficiency: a targeted review of the literature and foundation reports","volume":"29","author":"Zhang","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.cll.2026.02.003_bib22","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1182\/blood.2023020721","article-title":"Factor XI deficiency: phenotypic age-related considerations and clinical approach towards bleeding risk assessment","volume":"143","author":"Barg","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.cll.2026.02.003_bib23","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1182\/blood.2023020719","article-title":"Biology of factor XI","volume":"143","author":"Moellmer","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.cll.2026.02.003_bib24","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.jtha.2023.12.038","article-title":"Thrombin activation of the factor XI dimer is a multistaged process for each subunit","volume":"22","author":"Bar Barroeta","year":"2024","journal-title":"J Thromb Haemostasis"},{"key":"10.1016\/j.cll.2026.02.003_bib25","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1056\/NEJM199107183250303","article-title":"Factor XI deficiency in Ashkenazi Jews in Israel","volume":"325","author":"Asakai","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cll.2026.02.003_bib26","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1080\/17474086.2016.1191944","article-title":"Why factor XI deficiency is a clinical concern","volume":"9","author":"Wheeler","year":"2016","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.cll.2026.02.003_bib27","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1161\/ATVBAHA.117.309846","article-title":"Tissue factor: an essential mediator of hemostasis and trigger of thrombosis","volume":"38","author":"Grover","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cll.2026.02.003_bib28","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1055\/a-2091-7006","article-title":"Monocyte tissue factor expression: lipopolysaccharide induction and roles in pathological activation of coagulation","volume":"123","author":"Sachetto","year":"2023","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.cll.2026.02.003_bib29","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1182\/blood-2009-05-219915","article-title":"Coagulation factors IX through XIII and the risk of future venous thrombosis: the longitudinal investigation of thromboembolism etiology","volume":"114","author":"Cushman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.cll.2026.02.003_bib30","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1182\/blood-2005-12-023697","article-title":"Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: opposite and synergistic effects of factors XI and XII","volume":"108","author":"Doggen","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.cll.2026.02.003_bib31","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/j.1538-7836.2007.02530.x","article-title":"Evidence of a U-shaped association between factor XII activity and overall survival","volume":"5","author":"Endler","year":"2007","journal-title":"J Thromb Haemostasis"},{"key":"10.1016\/j.cll.2026.02.003_bib32","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/rth2.12162","article-title":"Polyphosphate in thrombosis, hemostasis, and inflammation","volume":"3","author":"Baker","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.cll.2026.02.003_bib33","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1038\/s41598-021-81268-7","article-title":"Neutrophils can promote clotting via FXI and impact clot structure via neutrophil extracellular traps in a distinctive manner in vitro","volume":"11","author":"Shi","year":"2021","journal-title":"Sci Rep"},{"issue":"Suppl 1","key":"10.1016\/j.cll.2026.02.003_bib34","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1111\/jth.12961","article-title":"Medical device-induced thrombosis: what causes it and how can we prevent it?","volume":"13","author":"Jaffer","year":"2015","journal-title":"J Thromb Haemostasis"},{"key":"10.1016\/j.cll.2026.02.003_bib35","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1055\/s-0037-1603937","article-title":"Inhibition of factors XI and XII for prevention of thrombosis induced by artificial surfaces","volume":"44","author":"Tillman","year":"2018","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.cll.2026.02.003_bib36","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1182\/asheducation-2014.1.66","article-title":"Epidemiologic and clinical data linking factor XI and factor XII to thrombosis","volume":"20","author":"Key","year":"2014","journal-title":"Hematology, ASH Education Program"},{"key":"10.1016\/j.cll.2026.02.003_bib37","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1111\/ene.15820","article-title":"Leveraging genetic predictors of factor XI levels to anticipate results from clinical trials","volume":"30","author":"Daghlas","year":"2023","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.cll.2026.02.003_bib38","doi-asserted-by":"crossref","DOI":"10.1093\/ehjopen\/oeae043","article-title":"Genetic assessment of efficacy and safety profiles of coagulation cascade proteins identifies factors II and XI as actionable anticoagulant targets","volume":"4","author":"Gagnon","year":"2024","journal-title":"Eur Heart J Open"},{"key":"10.1016\/j.cll.2026.02.003_bib39","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1161\/STROKEAHA.118.022792","article-title":"Genetically determined FXI (factor XI) levels and risk of stroke","volume":"49","author":"Gill","year":"2018","journal-title":"Stroke"},{"key":"10.1016\/j.cll.2026.02.003_bib40","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1160\/TH10-05-0307","article-title":"Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis","volume":"105","author":"Salomon","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.cll.2026.02.003_bib41","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1182\/blood-2016-09-742262","article-title":"Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events","volume":"129","author":"Preis","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.cll.2026.02.003_bib42","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1182\/blood-2007-10-120139","article-title":"Reduced incidence of ischemic stroke in patients with severe factor XI deficiency","volume":"111","author":"Salomon","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.cll.2026.02.003_bib43","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1056\/NEJM200003093421004","article-title":"High levels of coagulation factor XI as a risk factor for venous thrombosis","volume":"342","author":"Meijers","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cll.2026.02.003_bib44","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1111\/j.1538-7836.2009.03544.x","article-title":"Genetic variants associated with deep vein thrombosis: the F11 locus","volume":"7","author":"Li","year":"2009","journal-title":"J Thromb Haemostasis"},{"key":"10.1016\/j.cll.2026.02.003_bib45","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1160\/th15-06-0459","article-title":"F11 is associated with recurrent VTE in women. A prospective cohort study","volume":"115","author":"Bruzelius","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.cll.2026.02.003_bib46","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/jth.12531","article-title":"Antigen levels of coagulation factor XII, coagulation factor XI and prekallikrein, and the risk of myocardial infarction and ischemic stroke in young women","volume":"12","author":"Siegerink","year":"2014","journal-title":"J Thromb Haemostasis"},{"key":"10.1016\/j.cll.2026.02.003_bib47","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1309\/QC259F09UNMKVP0R","article-title":"Elevated factor XI activity levels are associated with an increased odds ratio for cerebrovascular events","volume":"126","author":"Yang","year":"2006","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.cll.2026.02.003_bib48","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1159\/000297966","article-title":"Novel hemostatic factor levels and risk of ischemic stroke: the atherosclerosis risk in communities (ARIC) study","volume":"29","author":"Suri","year":"2010","journal-title":"Cerebrovasc Dis"},{"key":"10.1016\/j.cll.2026.02.003_bib49","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0049-3848(02)00190-1","article-title":"Elevated levels of factor XI are associated with cardiovascular disease in women","volume":"107","author":"Berliner","year":"2002","journal-title":"Thromb Res"},{"key":"10.1016\/j.cll.2026.02.003_bib50","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1161\/ATVBAHA.113.301282","article-title":"Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates","volume":"33","author":"Crosby","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cll.2026.02.003_bib51","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13784","article-title":"Pharmacokinetics, pharmacodynamics, and safety of fesomersen, a novel antisense inhibitor of factor XI, in healthy Chinese, Japanese, and Caucasian volunteers","volume":"17","author":"Liu","year":"2024","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.cll.2026.02.003_bib52","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1016\/j.jmb.2019.09.008","article-title":"Allosteric inhibition as a new mode of action for BAY 1213790, a neutralizing antibody targeting the activated form of coagulation factor XI","volume":"431","author":"Schaefer","year":"2019","journal-title":"J Mol Biol"},{"key":"10.1016\/j.cll.2026.02.003_bib53","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/blood.2021011725","article-title":"The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial","volume":"138","author":"Lorentz","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.cll.2026.02.003_bib54","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/jth.15577","article-title":"Pharmacokinetics and pharmacodynamics of abelacimab (MAA868), a novel dual inhibitor of factor XI and factor XIa","volume":"20","author":"Yi","year":"2022","journal-title":"J Thromb Haemostasis"},{"key":"10.1016\/j.cll.2026.02.003_bib55","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/jth.15700","article-title":"Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa","volume":"20","author":"Heitmeier","year":"2022","journal-title":"J Thromb Haemostasis"},{"key":"10.1016\/j.cll.2026.02.003_bib56","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1021\/acs.jmedchem.1c00613","article-title":"Discovery of milvexian, a high-affinity, orally bioavailable inhibitor of factor XIa in clinical studies for antithrombotic therapy","volume":"65","author":"Dilger","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.cll.2026.02.003_bib57","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.jtha.2025.02.025","article-title":"Anticoagulant drugs targeting factor XI\/XIa and coagulation tests: we urgently need reliable pharmacodynamic data","volume":"23","author":"Gouin-Thibault","year":"2025","journal-title":"J Thromb Haemostasis"},{"key":"10.1016\/j.cll.2026.02.003_bib58","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cll.2026.02.003_bib59","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1056\/NEJMoa2406674","article-title":"Abelacimab versus rivaroxaban in patients with atrial fibrillation","volume":"392","author":"Ruff","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cll.2026.02.003_bib60","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0140-6736(22)01588-4","article-title":"Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"400","author":"Shoamanesh","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cll.2026.02.003_bib61","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.thromres.2024.03.001","article-title":"Asundexian in atrial fibrillation: can pharmacodynamic data explain the failure?","volume":"236","author":"Vassart","year":"2024","journal-title":"Thromb Res"},{"key":"10.1016\/j.cll.2026.02.003_bib62","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"B\u00fcller","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cll.2026.02.003_bib63","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2019.20687","article-title":"Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial","volume":"323","author":"Weitz","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.cll.2026.02.003_bib64","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the prevention of venous thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cll.2026.02.003_bib65","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.903029","article-title":"Factor XI inhibitors for prevention and treatment of venous thromboembolism: a review of the rationale and update on current evidence","volume":"9","author":"Nopp","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.cll.2026.02.003_bib66","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cll.2026.02.003_bib67","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.122.061612","article-title":"A multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor XIa inhibitor Asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction","volume":"146","author":"Rao","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.cll.2026.02.003_bib68","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1474-4422(23)00403-9","article-title":"Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial","volume":"23","author":"Sharma","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.cll.2026.02.003_bib69","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa2407105","article-title":"Asundexian versus apixaban in patients with atrial fibrillation","volume":"392","author":"Piccini","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cll.2026.02.003_bib70","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ahj.2024.08.011","article-title":"Milvexian vs apixaban for stroke prevention in atrial fibrillation: the LIBREXIA atrial fibrillation trial rationale and design","volume":"277","author":"Jain","year":"2024","journal-title":"Am Heart J"},{"key":"10.1016\/j.cll.2026.02.003_bib71","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ahj.2025.02.011","article-title":"Oral factor XIa inhibitor milvexian after a recent acute coronary syndrome: rationale and design of the phase 3 (LIBREXIA ACS)","volume":"285","author":"Gibson","year":"2025","journal-title":"Am Heart J"},{"key":"10.1016\/j.cll.2026.02.003_bib72","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.3390\/jcm11133788","article-title":"Effectiveness and safety of apixaban in over 3.9 million people with atrial fibrillation: a systematic review and meta-analysis","volume":"11","author":"Buckley","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.cll.2026.02.003_bib73","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cll.2026.02.003_bib74","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Clinics in Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027227122600003X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027227122600003X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T18:03:35Z","timestamp":1783620215000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S027227122600003X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":74,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S027227122600003X"],"URL":"https:\/\/doi.org\/10.1016\/j.cll.2026.02.003","relation":{},"ISSN":["0272-2712"],"issn-type":[{"value":"0272-2712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacologic Factor XI\/XIa Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Clinics in Laboratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cll.2026.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}